A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs THR 317 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors ThromboGenics
- 11 May 2017 According to a ThromboGenics media release, first results are expected in H1 2018.
- 10 Jan 2017 According to a ThromboGenics media release, first patients has been enrolled in this trial. The first results from the study are expected in Q1 2018.
- 23 May 2016 New trial record